💨 Abstract
Verve Therapeutics Inc. (VERV) reported a first-quarter loss of $31 million, or 35 cents per share, exceeding Wall Street expectations of a 71 cents per share loss. The company's revenue was $33 million, surpassing the forecasted $7.1 million.
Courtesy: wtop.com
Suggested
‘All kinds of nutty about climate.’ New York’s Rochester draws residents fleeing extreme weather -
California governor proposes pausing expansion of health care to low-income immigrants -
Raphinha’s breakthrough season key for Barcelona as it nears Spanish league title -
Jueza avala que Trump use Ley de Enemigos Extranjeros para deportar a venezolanos ligados al Tren de Aragua -
“Que nos den una fe de vida”: cómo deportaciones del Gobierno de Trump impiden a familiares saber dónde están seres queridos -
California Gov. Newsom wants to pause enrollment of more immigrants without legal status in state-funded health program -
Funds from migrants sent back home help fuel some towns’ economies. A GOP plan targets that -
Star Equity: Q1 Earnings Snapshot -
Cámara Argentina de Comercio Electrónico: “El costo impositivo argentino es muy alto” -
¿Saldrán de prisión los hermanos Menéndez? Lo que sabemos tras la nueva sentencia -